Literature DB >> 22384203

MCP1 SNPs and pulmonary tuberculosis in cohorts from West Africa, the USA and Argentina: lack of association or epistasis with IL12B polymorphisms.

Digna R Velez Edwards1, Alessandra Tacconelli, Christian Wejse, Philip C Hill, Gerard A J Morris, Todd L Edwards, John R Gilbert, Jamie L Myers, Yo Son Park, Martin E Stryjewski, Eduardo Abbate, Rosa Estevan, Paulo Rabna, Giuseppe Novelli, Carol D Hamilton, Richard Adegbola, Lars Østergaar, Scott M Williams, William K Scott, Giorgio Sirugo.   

Abstract

The monocyte chemotactic protein-1 (MCP-1) is a chemokine that plays an important role in the recruitment of monocytes to M. tuberculosis infection sites, and previous studies have reported that genetic variants in MCP1 are associated with differential susceptibility to pulmonary tuberculosis (PTB). We examined eight MCP1 single nucleotide polymorphisms (SNPs) in a multi-ethnic, case-control design that included: 321 cases and 346 controls from Guinea-Bissau, 258 cases and 271 controls from The Gambia, 295 cases and 179 controls from the U.S. (African-Americans), and an additional set of 237 cases and 144 controls of European ancestry from the U.S. and Argentina. Two locus interactions were also examined for polymorphisms in MCP1 and interleukin 12B (IL12B), another gene implicated in PTB risk. Examination of previously associated MCP1 SNPs rs1024611 (-2581A/G), rs2857656 (-362G/C) and rs4586 (+900C/T) did not show evidence for association. One interaction between rs2857656 and IL12B SNP rs2288831 was observed among Africans but the effect was in the opposite direction in Guineans (OR = 1.90, p = 0.001) and Gambians (OR = 0.64, p = 0.024). Our data indicate that the effect of genetic variation within MCP1 is not clear cut and additional studies will be needed to elucidate its role in TB susceptibility.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22384203      PMCID: PMC3288089          DOI: 10.1371/journal.pone.0032275

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Approximately one third of the world's population is infected with Mycobacterium tuberculosis (Mtb) with a global burden of TB disease in 2009 of 9.4 million incident cases, 14 million prevalent cases and more than 1.6 million deaths. According to the 2010 WHO global report on TB, the great majority of cases were in the South-East Asia, Africa and the Western Pacific (35%, 30% and 20%, respectively). An estimated 11–13% of incident cases were HIV-positive and approximately 80% of these cases were in Africa [1]. However, the majorities of those infected with Mtb maintain a latent state and do not convert to clinical disease but do remain at risk of progressing to active TB later. Factors that can modulate progression to active TB include gender, anemia, smoking and alcohol consumption as well as bacterial and host genetic factors [2]–[4]. In addition, increasing rates of TB and HIV have been highly correlated and a large percentage of TB cases are HIV-positive. Nonetheless, a substantial proportion of risk remains unexplained [5]. Evidence from human and animal studies indicates that Mtb clearance is genetically regulated [6]. Twin studies, genome-wide linkage and association analyses as well as candidate gene studies support the notion that human genetic factors play a role in the development of TB [7]–[9] and the majority of genes that have been implicated so far are in immunological pathways [8]. However, studies implicating genetic loci or specific genes have sometimes been inconsistent, possibly due to heterogeneity in phenotype definitions and study populations. Such heterogeneities are common challenges in global studies of etiologically complex traits, such as risk for Mtb infection and progression to TB [10]. The chemokine (C-C motif) ligand 2/monocyte chemotactic protein 1 gene (CCL2/MCP1) encodes the CCL2/MCP-1 protein, a member of the CC chemokine subfamily that is characterized by a two cysteine residue motif proximal to the amino-terminus of the protein. The MCP-1 chemokine plays a key role in the granulomatous reaction in lung tissue and Mtb containment in mouse models occurs through an interaction with the cognate receptor, chemokine (C-C motif) receptor 2 (CCR2), expressed on monocytes, macrophages, CD4+ T cells and immature dendritic cells [11]. The chemokine MCP-1 was associated with severe tuberculosis and was proposed as a marker of disease severity [12]. The 17q11-q21 chromosomal region encompassing MCP1 was initially identified as a candidate for TB susceptibility in linkage analyses of multi-case tuberculosis and leprosy families from Brazil and the critical interval was subsequently refined to 17q11.12 [13]. An MCP1 promoter variant has been associated with increased susceptibility to pulmonary TB (PTB), which is mediated through the inhibition of cytokine IL-12p40 production and is required for IFNγ-induced protection from PTB. Functional studies by Flores-Villanueva et al. showed that the GG genotype at MCP1 “−2518” (alias −2581 used in this paper, rs1024611) had the highest MCP-1 plasma levels and lowest IL-12p40 plasma concentrations in TB patients [14]; IL-12p40 (encoded by IL12B) is required for IFNγ-induced protection from PTB and the GG homozygotes had 5× higher odds of developing TB than AA homozygotes [14]. The same SNP has also been associated with modulation of risk for spina bifida, coronary artery disease, and HIV-1, suggesting that rs1024611 could be a pleiotropic mutation with effects on different but key biological pathways [15]–[17]. Based on the potential biological role of MCP1 in PTB susceptibility and previous evidence implicating this gene, we undertook this study to investigate the association of gene variants of MCP1 with susceptibility to PTB in two West African populations (Guinea-Bissau and The Gambia) and to replicate the results in African-Americans and samples of European ancestry from North and South America. We assayed eight SNPs in MCP1 in DNA samples from 321 PTB cases and 346 controls from Guinea-Bissau, 258 PTB cases and 271 controls from The Gambia, 295 cases and 179 controls that are African-Americans, and 237 cases and 144 controls of European ancestry from North and South America. Genetic data were evaluated for association with PTB risk. In addition, motivated by our previous findings of an association between IL12B and PTB and the known biological interaction between the gene products, we assessed whether polymorphisms in IL12B modify PTB susceptibility due to MCP1 variation [18].

Materials and Methods

Study Populations

Detailed clinical and demographic information for subjects from Guinea-Bissau, The Gambia, the United States (African-Americans) and North and South Americans of European ancestry has been previously published [19]–[21]. A summary of basic demographic characteristics and study samples sizes is provided in Table 1.
Table 1

Demographic data summary.

Guineans (Guinea-Bissau)GambiansAfrican-AmericansEuropean Americans/Argentinians
Cases(N = 321)Controls(N = 346)Cases(N = 258)Controls(N = 271)Cases(N = 295)Controls(N = 179)Cases(N = 237)Controls(N = 144)
Age, mean ± SD, (years)37.08±13.7335.58±12.4033.34±13.6329.09±13.1445.48±17.8651.91±21.2439.20±17.6140.67±20.28
Sex (%)
Male60.4449.7169.3869.7465.9783.5352.2062.12
Female35.5650.2930.6230.2634.0216.4747.737.0
Ethnicity (%)
Balanta15.2619.36 - - - - - -
Fulani14.9511.5612.186.27 - - - -
Jola--21.4334.12
Mancanha8.1012.43-- - - - -
Mandinka7.487.5139.0832.55 - - - -
Manjaco19.009.54-- - - - -
Papel20.2529.77--
Wolof--11.3413.33 - - - -
Other14.959.8315.9713.73 - -

Guinea-Bissau

This case-control study was conducted at the Bandim Health Project (BHP), a demographic surveillance site in Bissau, the capital of Guinea-Bissau. The incidence of PTB in this area is among the highest in the world, 470/100,000. Our Guinean cohort consisted of Papel (25%), Balanta (17%), Manjaco (14%), Fulani (13%), Mancanha (10%), Mandinka (7%), and other ethnicities (12%). Cases were residents or long-term guests of Bissau, aged greater than 15 years and newly diagnosed with PTB using three sputum examinations for acid fast bacteria or clinical criteria by the World Health Organization's definition of active pulmonary TB [22]. No culture confirmation of TB was available in Bissau during the study period, as facilities were destroyed during a civil war; 218/321 (68%) cases were smear positive. Patients with newly diagnosed TB were enrolled when they started antitubercular treatment at local health centers. During the inclusion period from November 2003 to November 2005, 438 TB patients were screened at local health centers: 344 subjects met inclusion criteria and provided written informed consent, and from these we could obtain 321 DNA samples. Healthy controls were recruited from the study area from May 2005 to November 2005. A random sample of 200 houses was selected from the database of all subjects living in the study area; houses with a recorded case of TB within the past 2 years were excluded from the sampling. Exclusion criteria for controls included the presence of cough for more than 2 weeks, history of TB and TB in the household within the last 2 years to avoid households with a high-risk of active TB. The composition of the case and control samples was different in terms of sex and ethnicity. These differences are due to the sampling strategy as controls were derived from healthy nuclear families; hence more healthy married couples were collected, whereas TB patients are more often males. The ethnic differences are due to willingness of healthy subjects to give blood, which was not the same across the ethnic groups, whereas most TB patients agreed to participate in the study regardless of their ethnic background. All controls were unrelated to cases. Analyses were also performed excluding cases who only had clinical diagnoses to test for the effect of these samples on our results (Table S1). All subjects were interviewed by field assistants, using a standardized questionnaire on ethnicity, environmental factors and prior exposure to TB. Permission to perform HIV tests was obtained for cases but not for controls, as requiring HIV testing would have negatively impacted participation in the study. Venous blood samples were collected from all subjects. Ethical approval was granted by the ‘Unidade de Coordenacao de Estudos e Pesquisas em material de Saude’ (Ministry of Health) in Guinea-Bissau. All adults and children's guardians signed a written informed consent to the study.

The Gambia

Between June 2002 and October 2004, PTB cases and their household contacts were enrolled in a prospective cohort study in the Greater Banjul region of The Gambia, where about 750,000 people live, representing more than 50% of the total Gambian population (http://www.columbia.edu/~msj42/index.htm). Our Gambian cohort consisted of Mandinka (36%), Jola (28%), Wolof (12%), Fulani (9%), and other ethnicities (15%). According to WHO 2007 burden estimates, the incidence of TB in The Gambia is 258/100,000 and 11% of new TB cases are HIV positive (http://www.who.int/globalatlas/predefinedReports/TB/PDF_Files/gmb.pdf). Recruitment took place at the major government TB clinic and the Medical Research Council (MRC) outpatient clinic, and consisted of sputum smear positive pulmonary TB cases at least 15 years old, who had at least one household contact living with them [19]. HIV positive patients were excluded from the study, and all included patients had two positive sputum smear samples for acid-fast bacilli and Mtb isolated upon culture. An index case was defined as the first TB case identified in a household. Household contact controls were defined as individuals living the majority of the time on the same compound as the index TB case, sharing meals and identifying a common household head. Written informed consent was obtained from all subjects, including parents/guardians for minors. The study was approved by the combined Gambia Government/MRC National Ethics Committee of The Gambia. Subjects were interviewed by field assistants, using a standardized questionnaire on ethnicity, environmental factors and prior exposure to TB. Permission to perform HIV tests was asked for cases but not for controls. Venous blood samples were collected from all subjects, and from these, 258 case DNA samples and 271 control DNA samples (unrelated to cases) were genotyped for analyses. All samples were archived in the National Gambian DNA Bank and used in compliance with the bank guidelines [23].

African-Americans, European ancestry Americans and Argentineans

Participants were ascertained through the North Carolina or South Carolina TB Control Programs, U.S.A., or as patients at the outpatient clinic at F.J. Muñiz Hospital in Buenos Aires, Argentina, between 2002 and 2006. Criteria for inclusion as TB cases were: a) age 14 years of age or older and culture-confirmed PTB, or b) younger than 14 years old and either culture-confirmed or clinically diagnosed PTB that included a positive tuberculin skin test plus an infiltrate or hilar adenopathy on chest x-ray. Some of the cases only had clinical diagnoses (7% for the African-American and European-American cases and 4% for the Argentinean cases). To test for the effect of these samples on the results they were excluded in a set of sensitivity analyses (Table S1). Individuals were eligible to participate if TB had been diagnosed in the past, or if they were currently receiving TB treatment. All TB cases remained eligible if they also had a diagnosis of extrapulmonary TB. Family members of eligible TB cases, who themselves had a history of TB, were enrolled as part of a multi-case family if review of their records established diagnosis of either pulmonary or extrapulmonary TB. Thus, a small portion of our study subjects enrolled as part of a multi-case family had extrapulmonary TB only. Severity of TB disease was assessed by presence of acid-fast bacilli (AFB) in sputum smears (7% African-Americans, 4% European-Americans/Argentineans) or x-ray evidence of cavitary lesions. We attempted to document HIV status through medical record review for all subjects. However, participation in this study did not require that the individual authorize review of HIV test results. Unaffected individuals who were in close contact with cases, such as household contacts such as spouses and partners, and relatives such as parents and siblings, were enrolled as controls. Written informed consent was obtained from all subjects or their legal representatives before participation in the study. Human experimentation guidelines of the U.S. Department of Health and Human Services and those of the participating research institutions were followed. The protocol was IRB-approved at Duke University Medical Center, the North and South Carolina Departments of Public Health (USA), Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno” (CEMIC), the F.J. Muñiz Hospital, Buenos Aires, Argentina, and the University of Miami Miller School of Medicine.

DNA extraction and genotyping

SNPs were selected based on either being associated with PTB in previous studies (rs1024611, rs2857656 and rs4586) or being a haplotype tagging SNP in the MCP1 gene [14], [24], [25]. Tags were selected from HapMap phase III samples: African-Americans (from the SW USA), Africans (Yoruba, Maasai, and Luhya), Mexicans (from Los Angeles, USA) and Northern and Western Europeans (Centre d'Etude du Polymorphisme Humain (CEPH) family samples from Utah, USA) (http://www.hapmap.org). To focus analysis on common variants for which these samples have the greatest statistical power to detect effects, SNPs with minor allele frequency greater or equal to 0.1 and located in a region extending 3 kb on either side of the gene were identified from the HapMap and Genome Variation Server databases and were grouped into bins of highly correlated SNPs (r2 greater than or equal to 0.80). A single “tagSNP” was selected from each bin for genotyping. A summary of the SNPs examined is provided (Figure 1).
Figure 1

MCP1 Gene Structure and SNP Positions.

MCP1 is oriented 5′ to 3′ with SNPs indicated above the gene with rs numbers and position relative to coding sequence start site.

MCP1 Gene Structure and SNP Positions.

MCP1 is oriented 5′ to 3′ with SNPs indicated above the gene with rs numbers and position relative to coding sequence start site. All DNA samples were extracted using a standard salting-out procedure (Guinea-Bissau and The Gambia) or the Puregene method from Gentra systems (African-Americans and European-Americans/Argentineans). DNA purities were estimated spectrophotometrically, and final concentrations were determined by PicoGreen. One of the SNPs (rs1024611) genotyped in Guinea-Bissau and The Gambia samples was genotyped by TaqMan assay (ABI, Applera International Inc, Foster City, CA, USA) in 10 µl reaction volume, using the Rotor-Gene 3000 (Corbett Robotics Pty Ltd, Brisbane, Queensland, Australia) and the ABI 7500 real-time PCR system. Fluorescence curves were analyzed with the Rotor-Gene Software version 6 and the 7500 Sequence Detection Software version 1.2.1 for allelic discrimination. The remaining SNPs in all populations (Guinea-Bissau, The Gambia, African-Americans, and European-Americans/Argentineans) were genotyped using TaqMan assays on an ABI 7900 HT with genotype calling performed using ABI SDS software. All SNPs used in this study had genotyping call rates of 95% or better (mean call rates of 98%) and quality control duplicate sample match rates of 100%.

Bioinformatics Tools

SNP base pair (bp) position and function was identified using the SNPper (http://snpper.chip.org) database NCBI Build 35.1 (Figure 1). The HapMap database (http://www.hapmap.org) was used to obtain linkage disequilibrium (LD) and genotype information from the Yoruba and CEPH populations.

Statistical Methods

All analyses were performed separately for the four cohorts (Guinea-Bissau, The Gambia, African-Americans, and European-Americans/Argentineans). For Guinea-Bissau and The Gambia tests for deviations from Hardy-Weinberg Equilibrium (HWE) were performed using PLINK statistical software [26]. Tests for deviations from HWE in African-Americans and European-Americans/Argentineans were calculated using genetic data analysis (GDA) software using one case and one control from each pedigree [27]. Statistical significance for these analyses was determined using Fisher's exact test. Pairwise LD was characterized, standard summary statistics D′ and r2, and haplotype frequencies were calculated using HaploView statistical software [28]. Haplotype blocks were assigned, using the D′ confidence interval algorithm created by Gabriel et al. 2002 [29]. Haplotype analyses were performed Guinea Bissau and The Gambia with 3 and 8-marker sliding windows using PLINK software. Analyses were run using haplotype-bases association test with generalized linear models (GLMs) adjusting for age, sex, and ethnic group. Haplotype analyses only included common haplotypes (haplotype frequency ≥0.05) and statistical significance was assessed with 1,000 permutations to generate empirical p values. Single locus tests of association in Guinea-Bissau and The Gambia were performed using logistic regression models with PLINK software [26] assuming an additive genetic model. Odds ratios (ORs) and confidence intervals (CI) were reported for all statistical models. Confounding by age, ethnicity, and sex was evaluated in logistic regression models; for inclusion in the final model we required that a change in effect size for the SNP be greater than or equal to 0.05. As a result, all regression models were performed with an adjustment for age, ethnicity, and sex. Unadjusted models are presented in Table S2. A 2-degree of freedom genotypic test of association was also performed with PLINK software for Guinea-Bissau and The Gambia for model-free tests of association. For African-Americans and European-Americans/Argentineans single locus additive genotypic tests of association were performed with generalized estimating equations (GEE) using the independence correlation matrix implemented in STATA 11.0 statistical software (College Station, TX). GEE performs a valid test of gene×gene and gene×environment interactions in mixed family and case-control data [30]. We also performed GEE analyses adjusting for the potential confounders, age and sex for all analyses. For European-Americans/Argentineans we did the analyses two ways. First, we performed the analyses in these two cohorts separately; second, we incorporated ascertainment site in the models, using the combined data (Table S3). Because there was no evidence of a recruitment site effect between Argentinian and European-American cohorts, we pooled these samples in subsequent analyses. Two locus interaction analyses were performed to test for interactions between MCP1 and IL12B based on the observation in previous studies that a functional relationship exists between MCP1 promoter polymorphisms and IL12B concentrations [14]. The main effects for the polymorphisms examined in IL12B in our cohort have been previously published in Morris et al. 2011 [18] (a list of those variants is provided in Table S4). Two locus interactions were examined between MCP1 and IL12B polymorphisms with a MAF greater than 0.05 within a population and were performed with logistic regression for Guinea Bissau and The Gambia and with GEE for African-Americans and European-Americans/Argentineans using STATA 11.0 statistical software (College Station, TX). These analyses were performed adjusting for the same covariates used in single locus tests of associations. A Bonferroni correction for multiple testing was used to adjust for multiple testing for single locus and gene-gene interactions. Examination of allele and genotype frequency differences for cases with and without HIV indicated no evidence for significant differences between the two groups in any of the populations examined; as a result analyses were performed pooling cases with and without HIV. Sensitivity analyses were also performed by excluding clinically diagnosed TB cases for Guinea Bissau, African-Americans, and European-Americans/Argentineans. Overall, these analyses showed no difference in the association results. Finally, in order to assess the concordance of results across study populations meta-analyses of single SNP associations were performed using PLINK software [26]. Meta-analyses were run both including and excluding the European/Argentinean study population.

Results

Guinea-Bissau and The Gambia

Single locus tests of association did not identify a statistically significant association at any of the SNPs examined with either the logistic regression model for allelic association (Table 2) or using the 2 degree of freedom genotypic test (results not shown). A borderline association was observed in the Guinea-Bissau population but not in The Gambia at MCP1 marker rs2530797 with an OR = 1.39, 95% CI [0.95–2.02], p = 0.088 (Table 2). The association became less statistically significant for the dominant model (CC (referent) versus CT & TT, OR = 1.25, 95% CI [0.33–4.78], p = 0.742) and the recessive model (results not shown). Detailed analyses of the previously associated SNPs rs1024611 and rs2857656 demonstrated a borderline significant association in the Guinea-Bissau population for rs1024611 under the dominant model (AA (referent) versus AG & GG, OR = 1.36, 95% CI [0.96–1.93], p = 0.079) (Table 3). SNP rs2530797 was in LD with both previously associated SNPs rs1024611 (D′ = 1; r2 = 0.03) and rs2857656 (D′ = 1; r2 = 0.08) in the Guinea-Bissau population (Figure 2A and 2B). No statistically significant haplotype associations were found in the Guinean and Gambian cohorts (Table S5).
Table 2

Guineans and Gambians single locus association results adjusted for age, ethnicity and sex.

PopulationMarkerGenotypeGenotype CountsOR2 95% CIAdditivep-Value
CasesControlsLowerUpper
Guineansrs1024611* GG17211.230.921.630.163
AG123103
AA174217
rs10246101 TT200.640.361.150.137
AT2238
AA288305
rs3760396CC001.000.462.240.999
CG1616
GG293323
rs2857656CC56630.970.761.230.786
CG150158
GG107119
rs4586TT35291.050.811.360.702
CT129143
CC149169
rs39178911 TT1100.890.601.350.604
CT6970
CC244261
rs41416652CC00----
CT10
TT309342
rs2530797CC571.390.952.02 0.088
CT7159
TT240277
Gambiansrs1024611* GG18151.000.751.340.991
AG8093
AA138144
rs10246101 TT100.930.511.700.818
AT2429
AA219230
rs37603961 CC001.590.614.180.346
CG118
GG231253
rs2857656CC44500.940.721.220.623
CG116129
GG8081
rs4586TT22201.040.781.380.798
CT96109
CC126131
rs3917891TT660.860.591.250.427
CT5663
CC181187
rs41416652CC00----
CT00
TT247266
rs25307971 CC531.020.631.630.951
CT3844
TT204216

*Indicates a statistically significant deviation from HWE in either cases or controls.

A dominant model was used to calculate the association p value because the number of individuals in the rare homozygous class was below 5 in cases, controls, or both.

OR is for additive model except for those instances where a dominant model was used.

Table 3

Additive, dominant, and recessive regression models for SNPs previously associated in published studies adjusted for age, ethnicity and sex.

PopulationMarkerModelOR95% CIp-Value
LowUpper
Guineansrs1024611AA(referent) vs AG vs GG1.230.921.630.163
AA(referent) vs AG&GG1.360.961.93 0.079
AA&AG(referent) vs GG0.960.462.010.915
rs2857656GG(referent) vs GC vs CC0.970.761.230.786
GG(referent) vs GC&CC0.970.681.380.851
GG&GC(referent) vs CC0.940.611.460.792
Gambiansrs1024611AA(referent) vs AG vs GG1.000.751.340.991
AA(referent) vs AG&GG0.940.651.350.744
AA&AG(referent) vs GG1.280.622.650.499
rs2857656GG(referent) vs GC vs CC0.940.721.220.623
GG(referent) vs GC&CC0.900.621.330.611
GG&GC(referent) vs CC0.940.581.500.783
African-Americansrs1024611AA(referent) vs AG vs GG1.270.831.930.272
AA(referent) vs AG&GG1.310.812.100.270
AA&AG(referent) vs GG1.330.335.410.687
rs2857656GG(referent) vs GC vs CC1.120.602.090.717
GG(referent) vs GC&CC1.210.761.920.418
GG&GC(referent) vs CC0.660.351.250.204
European-Americans/Argentineansrs1024611AA(referent) vs AG vs GG1.180.632.230.599
AA(referent) vs AG&GG1.780.595.350.303
AA&AG(referent) vs GG0.960.362.530.933
rs2857656GG(referent) vs GC vs CC1.120.602.090.717
GG(referent) vs GC&CC1.820.615.470.285
GG&GC(referent) vs CC0.840.332.170.723
Figure 2

Guinea-Bissau and The Gambia HaploView plots for controls (MCP1).

LD plots are presented for Guinea Bissau controls (A and B) and for The Gambia controls (C and D) including both D′ and r2. All figures are oriented 5′ to 3′, right to left, relative to the gene orientation on the minus strand. D′ (shades of red) and r2 (shades of black) are indicated in percentages within squares in the LD plots, with solid blocks without numbers indicating D′ and r2 = 1. Strong LD is indicated by red or dark gray, while pink and light gray and white indicate uninformative and low confidence values, respectively. LD Blocks were created with the default algorithm in HaploView that creates 95% confidence bounds on D′ considered being in strong LD where 95% of the comparisons made are informative. The haplotype blocks were created using HaploView program, version 4.1.

Guinea-Bissau and The Gambia HaploView plots for controls (MCP1).

LD plots are presented for Guinea Bissau controls (A and B) and for The Gambia controls (C and D) including both D′ and r2. All figures are oriented 5′ to 3′, right to left, relative to the gene orientation on the minus strand. D′ (shades of red) and r2 (shades of black) are indicated in percentages within squares in the LD plots, with solid blocks without numbers indicating D′ and r2 = 1. Strong LD is indicated by red or dark gray, while pink and light gray and white indicate uninformative and low confidence values, respectively. LD Blocks were created with the default algorithm in HaploView that creates 95% confidence bounds on D′ considered being in strong LD where 95% of the comparisons made are informative. The haplotype blocks were created using HaploView program, version 4.1. *Indicates a statistically significant deviation from HWE in either cases or controls. A dominant model was used to calculate the association p value because the number of individuals in the rare homozygous class was below 5 in cases, controls, or both. OR is for additive model except for those instances where a dominant model was used. Interaction analyses revealed evidence for a gene-gene interaction between MCP1 SNP rs2857656 and IL12B SNP rs2288831 (Table S6, ORINT = 1.90, 95% CI [1.31–2.77], p = 0.001) in Guinea-Bissau; however, this result was not in the same direction in The Gambia, despite being statistically significant (p = 0.024). Neither of these results was significant after correction for multiple testing.

African-Americans and European-Americans/Argentineans

Single locus tests of association did not identify a statistically significant association at any of the SNPs in the African-American and European-American/Argentinean populations (Table 4). LD plots for African-American and for European-American/Argentinean controls are shown in Figure 3, respectively 3A–B and 3C–D. There were no statistically significant interactions between MCP1 and IL12B in European-Americans/Argentineans; however, in African-Americans there was one statistically significant interaction between MCP1 rs3917891 and IL12B rs11574790 (ORINT = 0.28, 95% CI [0.13–0.65], p = 0.003) (Table S6). None of the associations were statistically significant after correction for multiple testing.
Table 4

African-Americans and European-Americans/Argentineans single locus association results using an additive GEE model adjusted for age and sex.

PopulationMarkerGenotypeGenotype CountsOR2 95% CIAdditivep-Value
CasesControlsLowUpper
African-Americansrs10246111 GG841.310.832.050.243
AG9149
AA189123
rs10246101 TT201.070.542.130.848
AT3622
AA250151
rs37603961 CC101.290.692.390.425
CG2614
GG259158
rs2857656CC38270.990.711.380.947
CG14081
GG11165
rs4586TT42240.800.581.110.179
CT12460
CC12188
rs39178911 TT740.720.431.200.207
CT5950
CC222117
rs41416652CC10----
CT41
TT284174
rs25307971 CC1111.560.912.690.100
CT7339
TT202133
European-Americans/Argentiniansrs1024611GG68321.180.632.230.599
AG9553
AA7055
rs1024610TT560.700.192.550.585
AT5635
AA171102
rs37603961 CC350.550.231.290.168
CG4432
GG183103
rs2857656CC69331.120.602.090.717
CG9654
GG7154
rs4586TT44391.370.682.790.379
CT10257
CC8345
rs3917891TT00----
CT22
CC228140
rs414166521 CC1221.540.613.880.356
CT4717
TT176121
rs2530797CC14171.020.452.310.971
CT9753
TT11769

Statistical models for African-Americans included an adjustment for age and sex and European-Americans/Argentineans also included an adjustment for ascertainment site.

A dominant model was used to calculate the association p value because the number of individuals in the rare homozygous class was below 5 in cases, controls, or both.

OR is for additive model except for those instances where a dominant model was used.

Figure 3

African-Americans and European-Americans/Argentineans HaploView plots for controls (MCP1).

LD plots are presented for African-American controls (A and B) and for European-American/Argentinean controls (C and D) including both D′ and r2. All figures are oriented 5′ to 3′, right to left, relative to the gene orientation on the minus strand. D′ (shades of red) and r2 (shades of black) are indicated in percentages within squares in the LD plots, with solid blocks without numbers indicating D′ and r2 = 1. Strong LD is indicated by red or dark gray, while pink and light gray and white indicate uninformative and low confidence values, respectively. LD Blocks were created with the default algorithm in HaploView that creates 95% confidence bounds on D′ considered being in strong LD where 95% of the comparisons made are informative. The haplotype blocks were created using HaploView program, version 4.1.

African-Americans and European-Americans/Argentineans HaploView plots for controls (MCP1).

LD plots are presented for African-American controls (A and B) and for European-American/Argentinean controls (C and D) including both D′ and r2. All figures are oriented 5′ to 3′, right to left, relative to the gene orientation on the minus strand. D′ (shades of red) and r2 (shades of black) are indicated in percentages within squares in the LD plots, with solid blocks without numbers indicating D′ and r2 = 1. Strong LD is indicated by red or dark gray, while pink and light gray and white indicate uninformative and low confidence values, respectively. LD Blocks were created with the default algorithm in HaploView that creates 95% confidence bounds on D′ considered being in strong LD where 95% of the comparisons made are informative. The haplotype blocks were created using HaploView program, version 4.1. Statistical models for African-Americans included an adjustment for age and sex and European-Americans/Argentineans also included an adjustment for ascertainment site. A dominant model was used to calculate the association p value because the number of individuals in the rare homozygous class was below 5 in cases, controls, or both. OR is for additive model except for those instances where a dominant model was used. The strongest evidence for concordant single SNP association across study populations was for MCP1 rs2530797, (ORmeta = 1.30, random effect meta-analysis p = 0.051). Cochrane's Q statistic (p≥0.36) and the I2 index of heterogeneity (I≤3.36, scale 0–100) indicated little evidence for heterogeneity for this association across study populations for these SNPs. The results did not change when removing the European American/Argentinian sample (data not shown).

Discussion

In the present study we examined eight SNPs in MCP1 for association with PTB in two African populations, one African-American population, and populations of European ancestry from North and South America. We focused on variants that had been shown to be associated with either increased or decreased TB risk, although previous studies were inconsistent, possibly reflecting differences both in genetic structure and phenotype definitions. We did not observe any statistically significant association at the SNPs studied in Guineans, Gambians, African-Americans and European-Americans/Argentineans. Examination of all previously associated SNPs did not provide evidence for association in any of our populations. We observed a statistically significant interaction between MCP1 and IL12B in the West African cohorts; however, the association was in the opposite direction in the two populations, indicating that this is likely to be spurious. Our data is in contrast to the majority of that published to date (Table S7). Specifically for the SNPs we genotyped that have been previously examined we found: rs1024611 (−2581A/G) associations with PTB have been reported in Mexican, Korean, Ghanaian, Zambian, Tunisian, Moroccan and Peruvian cohorts [14], [24], [31]–[34]. This SNP, originally reported by Flores-Villanueva et al., promoted subsequent genetic studies of MCP1 and TB [14]. However, while in Ghanaians the “G” allele and the “AG+GG” genotypes were found to confer protection from PTB (OR = 0.81) [24], in a Moroccan sample only the “GG” genotype showed the same effect (OR = 0.35) [33]; in all other populations typed the “G” allele associated with increased risk (e.g. OR = 2.63 in Koreans, OR = 1.29 in Peruvians) [14], [34]. We also observed a trend in the direction of increased risk. The heterogeneous effect of the “G” allele was also reported in a meta-analysis by Feng et al. (Table S7) [35]. rs2857656 (−362G/C): in Ghanaians, the “C” allele and “CG+CC” genotypes were associated with protection from disease (OR = 0.83) [24]. In the same population, when SNPs rs1024611 and rs2857656 were combined in an extended haplotype including a 14 bp insertion/deletion, rs3917887 (haplotype: “rs1024611 G- rs2857656 C- rs3917887 del”), the protective effect size increased (OR = 0.78) [36], though the combination of genetic data with functional assays indicated that the role of rs1024611 was small at best. According to Thye et al. rs2857656 was the variant driving the protective effect originally observed in Ghanaians (see Table S7). Our data provide no evidence for association of rs2857656. rs4586 (+900C/T): the “C” allele and the “CC+TC” genotypes were associated with increased risk of TB (OR = 1.34 and 1.94, respectively), in a pediatric cohort from Northern China that was heterogeneous with respect to phenotype definitions, ranging from pulmonary TB (35%) to extra-pulmonary TB (26%) and TB meningitis (39%) [25]; moreover, the association was only found in males. This SNP was not significantly associated with TB in the Ghanaian study [24] nor in ours. Analyses of extended haplotypes in our Guineans and Gambians, encompassing polymorphisms associated with protection from TB in Ghanaians [36], did not reveal any association signal. Taken together our data do not support any of these previously associated variants. We also tested for interactions between MCP1 and IL12B based on prior experimental evidence supporting an interaction between these two genes [14] and our own recent study showing an IL12B association with PTB susceptibility in the same African ancestry samples examined in this paper [18]. Although we did observe some weak evidence for risk-modulating interactions in Guineans, Gambians and African-Americans, none of the MCP1-IL12B effects remained statistically significant after correction for multiple testing, and, most importantly, they were not always in the same direction. In conclusion, our data indicate that there was no evidence for a genetic interaction between MCP1 and IL12B with respect to susceptibility to PTB. In our study there were aspects that are worth discussing. We used two different ascertainment centers for the collection of European-ancestry samples, one from the Southeastern U.S. and another from Argentina, and they included a small number of HIV-positive cases as well as cases of extrapulmonary TB. In order to account for this we included ascertainment site as a variable in our models and performed sensitivity analyses excluding HIV-positive and extrapulmonary TB cases. Site, HIV status and extrapulmonary TB did not influence the significance of our results. Both the Guinea-Bissau and The Gambia population samples showed evidence for confounding by ethnic groups, but we dealt with this by adjustment for ethnicity. Finally, there were some limitations regarding power to detect effect sizes previously found. Within our Gambian cohort we had approximately 80% power to detect OR ranging between <0.49 or >1.8 with a MAF of 0.20, while, in our Guinea Bissau cohort with the same MAF we had 80% power to detect OR ranging between <0.53 >1.70. Although we were underpowered to detect associations of the effect size reported in the Ghanaian population (OR = 0.81 for rs1024611 and OR = 0.83 for rs2857656) [24], we failed to detect effects in the same direction as those previously published for both rs1024611 and rs2857656 in our West African samples. These discordant results are cause for caution in interpreting the role of MCP1 in TB susceptibility. However, it is possible that the lack of replication is due to unmeasured variables interacting with the MCP1 SNPs. Although we would have been able to have increased power by pooling the Guinea Bissau and Gambian cohorts, several studies have shown significant genetic heterogeneity across African populations, even within limited geographical areas [20], [37], and for this reason we chose not to pool our populations but instead to meta-analyze the results. Meta-analysis did not detect statistically significant, robust results across the studies. Our findings of interactions in opposite directions in these two cohorts support the decision not to pool. In conclusion, this study did not replicate associations with TB previously observed in MCP1. Although this is a highly relevant candidate gene, our data indicate that the effect of genetic variation within MCP1 is not clear cut and additional studies will be needed to elucidate its role in TB susceptibility. Sensitivity analysis including only culture confirmed or smear positive TB cases adjusted for covariates. (DOC) Click here for additional data file. Single locus tests of association in Guineans and Gambians unadjusted for age, sex and ethnicity. (DOC) Click here for additional data file. African-Americans and European-Americans/Argentineans single locus association results using an additive GEE model unadjusted for age and sex. (DOC) Click here for additional data file. IL12B polymorphisms examined in MCP1×IL12B interaction analyses. (DOC) Click here for additional data file. Guineans and Gambians 8 and 3 marker sliding window haplotype analysis. (DOC) Click here for additional data file. Top (p<0.05) gene×gene interaction (MCP1×IL12B) results across cohorts. Two locus interactions are presented between MCP1 and IL12B polymorphisms with a MAF greater than 0.05 within a population. These analyses were performed with logistic regression for Guinea Bissau and The Gambia and with GEE for African-Americans and European-Americans/Argentineans using STATA 11.0 statistical software (College Station, TX) and were performed adjusting for the same covariates used in single locus tests of associations. A Bonferroni correction for multiple testing was used to adjust for multiple testing for single locus and gene×gene interactions. The gene×gene interactions results are presented according to increasing p values. (DOC) Click here for additional data file. Genetic association of MCP1 variants with pulmonary tuberculosis. (DOC) Click here for additional data file.
  35 in total

Review 1.  Past, present and future directions in human genetic susceptibility to tuberculosis.

Authors:  Marlo Möller; Erika de Wit; Eileen G Hoal
Journal:  FEMS Immunol Med Microbiol       Date:  2009-08-19

Review 2.  Human genetic susceptibility to intracellular pathogens.

Authors:  Fredrik O Vannberg; Stephen J Chapman; Adrian V S Hill
Journal:  Immunol Rev       Date:  2011-03       Impact factor: 12.988

Review 3.  Tuberculosis as a complex trait: impact of genetic epidemiological study design.

Authors:  Catherine M Stein; Allison R Baker
Journal:  Mamm Genome       Date:  2010-11-23       Impact factor: 2.957

4.  Joint effect of MCP-1 genotype GG and MMP-1 genotype 2G/2G increases the likelihood of developing pulmonary tuberculosis in BCG-vaccinated individuals.

Authors:  Malathesha Ganachari; Jorge A Ruiz-Morales; Juan C Gomez de la Torre Pretell; Jeffrey Dinh; Julio Granados; Pedro O Flores-Villanueva
Journal:  PLoS One       Date:  2010-01-25       Impact factor: 3.240

5.  The genetic structure and history of Africans and African Americans.

Authors:  Sarah A Tishkoff; Floyd A Reed; Françoise R Friedlaender; Christopher Ehret; Alessia Ranciaro; Alain Froment; Jibril B Hirbo; Agnes A Awomoyi; Jean-Marie Bodo; Ogobara Doumbo; Muntaser Ibrahim; Abdalla T Juma; Maritha J Kotze; Godfrey Lema; Jason H Moore; Holly Mortensen; Thomas B Nyambo; Sabah A Omar; Kweli Powell; Gideon S Pretorius; Michael W Smith; Mahamadou A Thera; Charles Wambebe; James L Weber; Scott M Williams
Journal:  Science       Date:  2009-04-30       Impact factor: 47.728

Review 6.  Genetic studies of African populations: an overview on disease susceptibility and response to vaccines and therapeutics.

Authors:  Giorgio Sirugo; Branwen J Hennig; Adebowale A Adeyemo; Alice Matimba; Melanie J Newport; Muntaser E Ibrahim; Kelli K Ryckman; Alessandra Tacconelli; Renato Mariani-Costantini; Giuseppe Novelli; Himla Soodyall; Charles N Rotimi; Raj S Ramesar; Sarah A Tishkoff; Scott M Williams
Journal:  Hum Genet       Date:  2008-05-30       Impact factor: 4.132

7.  Polymorphism in CC-chemokine ligand 2 associated with tuberculosis in Zambia.

Authors:  P C A M Buijtels; W W J van de Sande; S Parkinson; P L C Petit; M A B van der Sande; D van Soolingen; H A Verbrugh; A van Belkum
Journal:  Int J Tuberc Lung Dis       Date:  2008-12       Impact factor: 2.373

8.  Association of SLC11A1 with tuberculosis and interactions with NOS2A and TLR2 in African-Americans and Caucasians.

Authors:  D R Velez; W F Hulme; J L Myers; M E Stryjewski; E Abbate; R Estevan; S G Patillo; J R Gilbert; C D Hamilton; W K Scott
Journal:  Int J Tuberc Lung Dis       Date:  2009-09       Impact factor: 2.373

9.  Interleukin 12B (IL12B) genetic variation and pulmonary tuberculosis: a study of cohorts from The Gambia, Guinea-Bissau, United States and Argentina.

Authors:  Gerard A J Morris; Digna R Velez Edwards; Philip C Hill; Christian Wejse; Cyrille Bisseye; Rikke Olesen; Todd L Edwards; John R Gilbert; Jamie L Myers; Martin E Stryjewski; Eduardo Abbate; Rosa Estevan; Carol D Hamilton; Alessandra Tacconelli; Giuseppe Novelli; Ercole Brunetti; Peter Aaby; Morten Sodemann; Lars Østergaard; Richard Adegbola; Scott M Williams; William K Scott; Giorgio Sirugo
Journal:  PLoS One       Date:  2011-02-09       Impact factor: 3.240

10.  CCL2 responses to Mycobacterium tuberculosis are associated with disease severity in tuberculosis.

Authors:  Zahra Hasan; Jacqueline M Cliff; Hazel M Dockrell; Bushra Jamil; Muhammad Irfan; Mussarat Ashraf; Rabia Hussain
Journal:  PLoS One       Date:  2009-12-29       Impact factor: 3.240

View more
  4 in total

1.  A Locus at 5q33.3 Confers Resistance to Tuberculosis in Highly Susceptible Individuals.

Authors:  Rafal S Sobota; Catherine M Stein; Nuri Kodaman; Laura B Scheinfeldt; Isaac Maro; Wendy Wieland-Alter; Robert P Igo; Albert Magohe; LaShaunda L Malone; Keith Chervenak; Noemi B Hall; Chawangwa Modongo; Nicola Zetola; Mecky Matee; Moses Joloba; Alain Froment; Thomas B Nyambo; Jason H Moore; William K Scott; Timothy Lahey; W Henry Boom; C Fordham von Reyn; Sarah A Tishkoff; Giorgio Sirugo; Scott M Williams
Journal:  Am J Hum Genet       Date:  2016-03-03       Impact factor: 11.025

2.  Genomics of human pulmonary tuberculosis: from genes to pathways.

Authors:  Catherine M Stein; Lindsay Sausville; Christian Wejse; Rafal S Sobota; Nicola M Zetola; Philip C Hill; W Henry Boom; William K Scott; Giorgio Sirugo; Scott M Williams
Journal:  Curr Genet Med Rep       Date:  2017-10-12

3.  Genetic association meta-analysis: a new classification to assess ethnicity using the association of MCP-1 -2518 polymorphism and tuberculosis susceptibility as a model.

Authors:  Tania Vásquez-Loarte; Milana Trubnykova; Heinner Guio
Journal:  BMC Genet       Date:  2015-10-30       Impact factor: 2.797

4.  Investigating the Role of Gene-Gene Interactions in TB Susceptibility.

Authors:  Michelle Daya; Lize van der Merwe; Paul D van Helden; Marlo Möller; Eileen G Hoal
Journal:  PLoS One       Date:  2015-04-28       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.